Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/24/2025

Apixaban Dosing Guidelines

Introduction to Apixaban Dosing

  • The European Society of Cardiology recommends a standard dose of 5 mg orally twice a day for most patients with non-valvular atrial fibrillation, reduced to 2.5 mg twice a day if the patient meets at least 2 of 3 reduction criteria (age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL) 1

Fibrilación Auricular No Valvular

  • For non-valvular atrial fibrillation, the standard dose is 5 mg orally twice a day for most patients, according to the European Heart Journal 1
  • The dose is reduced to 2.5 mg twice a day when the patient presents with at least 2 of the following 3 criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, as recommended by the European Heart Journal and Circulation 1, 2

Tratamiento de Tromboembolismo Venoso (TEV/EP)

  • The initial treatment dose for venous thromboembolism is 10 mg orally twice a day for the first 7 days, followed by 5 mg twice a day, as stated in the European Heart Journal 1
  • The maintenance dose after the first 7 days is 5 mg orally twice a day, continuing for at least 6 months, according to the European Heart Journal 1

Prevención de Recurrencia de TEV

  • For the prevention of recurrent venous thromboembolism, the dose is 2.5 mg orally twice a day after completing at least 6 months of initial anticoagulant treatment, as recommended by the European Heart Journal 1

Cardioversión en Fibrilación Auricular

  • For cardioversion with transesophageal echocardiography (TEE), at least one dose of apixaban ≥4 hours before the procedure is recommended by the European Heart Journal 1
  • An alternative strategy is anticoagulation with apixaban for at least 3 weeks before cardioversion (without TEE), as stated in the European Heart Journal 1

Consideraciones Especiales de Seguridad

  • The American College of Chest Physicians notes that apixaban has demonstrated a favorable bleeding profile compared to warfarina, with fewer major bleeding events 5
  • In the treatment of pulmonary embolism, the incidence of major bleeding was significantly lower with apixaban (0.6% vs 1.8%; relative risk 0.31; P<0.001), according to Praxis Medical Insights 4